Brief: Nicox Q3 Net Revenue At 2.4 Million Euros

Nicox SA

19/10/2021 07:08

Oct 19 (Reuters) - Nicox SA  NCOX.PA :
    * NET REVENUE OF EUR 2.4 MILLION IN Q3 OF 2021 AND CASH OF
EUR
32.7 MILLION ON SEPTEMBER 30, 2021
    * AS OF SEPTEMBER 30, 2021, THE NICOX GROUP HAD CASH AND
CASH
EQUIVALENTS OF €32.7 MILLION AS COMPARED WITH €36.5 MILLION AT
JUNE 30, 2021
    * AS OF SEPTEMBER 30, 2021,  NICOX GROUP HAD FINANCIAL DEBT
OF
€18.1 MILLION
    * NCX 470 IN GLAUCOMA: PHASE 3 CLINICAL TRIALS MONT BLANC
AND
DENALI RESULTS TO BE COMMUNICATED IN Q1 2023 AND BY END OF 2023
RESPECTIVELY.
    * NCX 4251 IN BLEPHARITIS: MEETING WITH U.S. FOOD AND DRUG
ADMINISTRATION IN EARLY 2022 TO DISCUSS NEXT DEVELOPMENT STEPS
BASED ON THE RECENTLY ANNOUNCED PHASE 2B TRIAL RESULTS.
    * ZERVIATETMIN ALLERGIC CONJUNCTIVITIS (CHINA): A PHASE 3
CLINICAL
TRIAL INTENDED TO SUPPORT AN APPLICATION FOR REGULATORY APPROVAL
IN CHINA, CONDUCTED AND FINANCED BY OUR PARTNER OCUMENSION, IS
ONGOING

Source text for Eikon:  ID:nGNE2JcVWT 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))